Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Kansas Gov. Parkinson Urged To Veto Removal Of Planned Parenthood Funding In Budget
Supporters of Planned Parenthood of Kansas and Mid-Missouri are urging Gov. Mark Parkinson (D) to veto a provision in a budget bill (H.B. 2373) that would eliminate the group"s funding, the AP/Wichita Eagle reports. The bill aims to balance Kansas" budget for the fiscal year that begins July 1. The original bill was approved by the Legislature and former Gov. Kathleen Sebelius, who resigned in April to become HHS secretary. It included $250,000 in state funding for Planned Parenthood for FY 2010. However, lawmakers later amended the budget with a new bill that includes a provision eliminating the funding after state revenue projections declined, the AP/Eagle reports.While antiabortion-rights advocates want Parkinson to retain the provision, about two dozen supporters of Planned Parenthood gathered on Tuesday to urge Parkinson to line-item veto the provision. They left petitions at the governor"s office with about 3,500 signatures, the AP/Eagle reports. Planned Parenthood attorney Pedro Irigonegarary said the loss of funding would negatively impact "a large number of innocent people." He added that the group "is about family values. They have taken those two words from us and now it"s time to take them back." According to the AP/Eagle, Planned Parenthood said the state funding is given to its Ellis and Sedgwick county clinics, which do not perform abortions. The group also noted that no state funds are used for abortion procedures performed at its clinics in Overland Park, a suburb of Kansas City.The governor"s office said that Parkinson intends to act on the bill sometime this week, although he will not announce what action he will take on any legislation in advance. Parkinson has said that he holds "very similar" views on abortion rights as Sebelius, who supports such rights. However, he has yet to act on any bills regarding abortion, the AP/Eagle reports. Mary Kay Culp, executive director of Kansans for Life, said that the group is asking members to contact legislators and the governor"s office in support of retaining the measure. The AP/Eagle reports that if Parkinson vetoes the measure, lawmakers could attempt to override it (Manning, AP/Wichita Eagle, 5/19).
generic viagra online
Varying Reductions In Breast Cancer Suggest Hormone Therapy To Blame
The recent decline in invasive breast cancer in the US was significantly less pronounced in the poor and those who live in rural areas. Researchers writing in the open access journal BMC Medicine suggest this may be due to varying reductions in the numbers of women taking hormone therapy (HT).
News of the day
Leave Fireworks To The Professionals This Fourth Of July
Each Fourth of July, thousands of people are injured from using consumer fireworks. According to the U.S. Consumer Product Safety Commission, more than 9,000 fireworks-related injuries happen each year. Of these, nearly half are head-related injuries with nearly 30 percent of these injuries to the eyes. One-fourth of fireworks eye injuries result in permanent vision loss or blindness.
Cardiovascular

Growing Midwestern Clinical Research Organization Selects OmniComm Systems To Provide EClinical Solutions For Phase IV Studies

OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials announced that a growing US Clinical Research Organization (CRO) has selected OmniComm to provide eClinical solutions in connection with two of the CRO"s Phase IV studies covering approximately 27 sites and more than 700 subjects. Additional details were not disclosed. Phase IV studies take place after a drug has been approved for marketing and are designed to provide broader experience in evaluating the safety and effectiveness of the new medicine in larger numbers of patients, subpopulations of patients, and to compare and/or combine it with other available treatments. "We are pleased to have been selected by this CRO to provide eClinical solutions for these important Phase IV studies," said Cornelis F. Wit, OmniComm"s President and CEO. "We believe the broad scope of our integrated eClinical solutions, enhanced by the recent acquisition of eResearch Technology"s data capture unit, positions us well to offer a broad array of solutions, especially for CRO"s, pharmaceutical, biotech and medical device companies seeking cost-effective tools to capture and track outcomes of clinical trials conducted at multiple locations. We look forward to expanding the range of services we provide for companies seeking to increase efficiencies in their clinical activities." About OmniComm OmniComm Systems, Inc. provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm"s growing base of satisfied customers is a direct result of the company"s commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm"s client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida and offices in Bonn, Germany, Tula, Russia, California, Connecticut, Georgia, Illinois, New Jersey, New York, North Carolina and Tennessee. Safe Harbor Disclaimer Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company"s ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company"s financial results can be found in the Company"s Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. OmniComm Systems, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009